Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Tremfya Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 2156-A

    Specialty Guideline Management Tremfya

    Customize your policy alerts

    Sign up for cvs_caremark Policy 2156-A alerts

    Get alerted when Policy 2156-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continuation of Tremfya for plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, subject to specified clinical, treatment, documentation, and prescriber requirements.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Tremfya
    Policy CodePolicy 2156-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the information required to initiate the Tremfya prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Covered FDA-approved indications
    12 monthsAuthorization duration
    6 years / 40 kgMinimum age and weight
    4Specialist prescriber pathways
    ProhibitedSame-indication combination therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    TB evaluationRequired safety evaluation

    General Coverage Requirements

    Initial Therapy — Plaque Psoriasis

    Covered when the member meets the applicable age, weight, prior-treatment, or disease-severity requirements below.

    ALL of the following

    • Member is 6 years of age or older and weighs at least 40 kg.
    • ONE of the following

      • Member has previously received a biologic or targeted synthetic drug (e.g., Sotyktu, Otezla) indicated for treatment of moderate to severe plaque psoriasis.
      • Disease-severity pathway

        • Member has moderate to severe plaque psoriasis.
        • ONE of the following

          • Crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas) are affected.
          • At least 10% of body surface area is affected.>= 10% BSA
          • At least 3% BSA plus ONE of the following

            • At least 3% of body surface area is affected.>= 3% BSA
            • ONE of the following

              • Member has had an inadequate response or intolerance to phototherapy (e.g., UVB or PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin.

    Initial Therapy — Psoriatic Arthritis

    Covered when the member meets the applicable age, weight, prior-treatment, or disease-severity requirements below.

    ALL of the following

    • Member is 6 years of age or older and weighs at least 40 kg.
    • ONE of the following

      • Member has previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Otezla) indicated for active psoriatic arthritis.
      • ONE of the following disease pathways

        • Mild to moderate disease and ONE of the following

          • Member has mild to moderate active psoriatic arthritis.
          • ONE of the following

    Initial Therapy — Ulcerative Colitis

    Covered when the member has the following condition.

    ALL of the following

    • Member has moderately to severely active ulcerative colitis.

    Initial Therapy — Crohn's Disease

    Covered when the member has the following condition.

    ALL of the following

    • Member has moderately to severely active Crohn's disease.

    Continuation Therapy — Plaque Psoriasis

    Authorization may be granted for 12 months, including for new members, when the member achieves or maintains a positive clinical response.

    ALL of the following

    • Member is 6 years of age or older and weighs at least 40 kg.
    • Member is using the requested medication for moderate to severe plaque psoriasis.
    • ONE of the following

      • Member has low disease activity or improvement in signs and symptoms of the condition.
      • There is a reduction in body surface area affected from baseline.
      • There is improvement from baseline in signs or symptoms, such as itching, redness, flaking, scaling, burning, cracking, or pain.

    Continuation Therapy — Psoriatic Arthritis

    Authorization may be granted for 12 months, including for new members, when the member achieves or maintains a positive clinical response.

    ALL of the following

    • Member is 6 years of age or older and weighs at least 40 kg.
    • Member is using the requested medication for psoriatic arthritis.
    • ONE of the following

      • Member has low disease activity or improvement in signs and symptoms of the condition.
      • Improvement from baseline in ONE or more of the following

        • Number of swollen joints.

    General Requirements

    The requested medication must be used for an FDA-approved indication and meet the applicable indication-specific initial or continuation criteria. Initial and continuation authorizations are generally granted for 12 months when the applicable requirements are satisfied.

    ALL of the following

    • The member meets the applicable indication-specific coverage criteria for plaque psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease.
    • The requested medication is not being used for an experimental or investigational indication.
    • The requested medication is prescribed and used in accordance with the applicable age, weight, disease-activity, prior-treatment, and response requirements.

    All-Indication Safety Requirements

    The following safety requirements apply to all indications.

    ALL of the following

    • Member has been evaluated for tuberculosis (TB) infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB.
    • Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

    Crohn's Disease — 12-Month Continuation Authorization

    Continuation authorization is issued for 12 months when the Crohn's disease response requirements are met.

    ALL of the following

    • The member is receiving the requested medication for moderately to severely active Crohn's disease.
    • ONE of the following

      • The member achieves or maintains remission.
      • The member has low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one recognized clinical, laboratory, endoscopic, imaging, or disease-activity measure.

    Treatment of adults and pediatric patients 6 years of age and older who weigh at least 40 kg with moderate to severe plaque psoriasis and who are candidates for systemic therapy or phototherapy; treatment of adults and pediatric patients 6 years of age and older who weigh at least 40 kg with active psoriatic arthritis; treatment of moderately to severely active ulcerative colitis in adults; and treatment of moderately to severely active Crohn's disease in adults. All other indications are considered experimental/investigational and not medically necessary.

    Tremfya cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    The requested medication cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Indications outside the specified FDA-approved uses—including plaque psoriasis that is not moderate to severe, psoriatic arthritis that is not active, ulcerative colitis that is not moderately to severely active, or Crohn's disease that is not moderately to severely active—are not covered and are considered experimental/investigational and not medically necessary.

    Clinical Thresholds and Eligibility

    Plaque psoriasis BSA and prior-treatment pathways
    Extensive involvementAt least 10% of body surface area (BSA) is affected.
    Limited involvementAt least 3% BSA is affected, with an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin.
    Treatment avoidance pathwayAt least 3% BSA is affected and there is a clinical reason to avoid methotrexate, cyclosporine, and acitretin.
    Alternative severity pathwayCrucial body areas, including the hands, feet, face, neck, scalp, genitals or groin, and intertriginous areas, are affected.
    Age and weight eligibility
    Minimum ageMembers must be 6 years of age or older.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    12-Month Initial Authorization

    Initial authorization may be granted for 12 months when the member meets the indication-specific eligibility requirements for plaque psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease.

    • Plaque psoriasis or psoriatic arthritis: member is at least 6 years old and weighs at least 40 kg.
    • Ulcerative colitis: moderately to severely active disease in an adult.
    • Crohn's disease: moderately to severely active disease in an adult.
    Prior Authorization

    12-Month Continuation Authorization

    Continuation authorization may be granted for 12 months, including for new members, when the member is using Tremfya for the covered indication and has achieved or maintained a positive clinical response.

    • Plaque psoriasis: low disease activity or improvement in affected body surface area, signs, or symptoms.
    • Psoriatic arthritis: low disease activity or improvement in disease manifestations from baseline.

    Medication and Policy Context

    Tremfya (guselkumab) is covered for selected inflammatory and immune-mediated conditions: moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis, and moderately to severely active Crohn's disease. Initial authorization is generally available for 12 months when indication-specific requirements are met. For plaque psoriasis and psoriatic arthritis, members must be at least 6 years old and weigh at least 40 kg; coverage may also depend on disease severity and prior treatment or treatment avoidance. Continued coverage requires documented clinical response, low disease activity, improvement, or— for ulcerative colitis and Crohn's disease—remission.

    Clinical Definitions

    Body surface area (BSA)
    DefinitionBSA is the body surface area affected by plaque psoriasis.
    Extensive involvement thresholdAt least 10% BSA affected is a qualifying plaque psoriasis criterion.
    Limited involvement thresholdAt least 3% BSA affected may qualify when specified treatment-response, intolerance, or treatment-avoidance criteria are also met.
    Enthesitis
    DefinitionEnthesitis is inflammation at the sites where tendons or ligaments attach to bone.
    Eligibility roleFor mild to moderate psoriatic arthritis, enthesitis is an alternative qualifying criterion for initial coverage.

    Initial Therapy by Indication

    Ulcerative Colitis Initial Therapy — 12-Month Authorization

    Authorization of 12 months may be granted for treatment of moderately to severely active ulcerative colitis.

    Member has moderately to severely active ulcerative colitis.

    Crohn's Disease Initial Therapy — 12-Month Authorization

    Authorization of 12 months may be granted for treatment of moderately to severely active Crohn's disease.

    Member has moderately to severely active Crohn's disease.

    Continuation Therapy by Indication

    Plaque Psoriasis Continuation — 12-Month Authorization

    Authorization of 12 months may be granted, including for new members, when positive clinical response criteria are met.

    ALL of the following

    • Member is at least 6 years of age, weighs at least 40 kg, and is using the requested medication for moderate to severe plaque psoriasis.Age >= 6 years; weight >= 40 kg
    • Positive clinical response

      • Reduction in body surface area affected from baseline.
      • Improvement from baseline in signs and symptoms, such as itching, redness, flaking, scaling, burning, cracking, or pain.

    Prior Treatment Pathways

    PathwayRequirementsCoverage
    Prior biologic or targeted synthetic therapyMember is at least 6 years old, weighs at least 40 kg, and previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.Covered
    Disease-severity pathway: crucial body areasMember is at least 6 years old, weighs at least 40 kg, has moderate to severe plaque psoriasis, and has involvement of crucial body areas such as the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas.Covered
    Disease-severity pathway: extensive involvementMember is at least 6 years old, weighs at least 40 kg, has moderate to severe plaque psoriasis, and at least 10% of body surface area is affected.Covered
    Disease-severity pathway: limited BSA with conventional-treatment criterionAt least 3% of body surface area is affected, and the member has an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin; or has a clinical reason to avoid methotrexate, cyclosporine, and acitretin.Covered
    PathwayRequirementsCoverage
    Prior biologic or targeted synthetic therapyMember is at least 6 years old, weighs at least 40 kg, and previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.Covered
    Mild to moderate disease: inadequate responseMember has mild to moderate active psoriatic arthritis and an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug, such as sulfasalazine, administered at an adequate dose and duration.Covered
    Mild to moderate disease: intolerance or contraindicationMember has mild to moderate active psoriatic arthritis and an intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug, such as sulfasalazine.Covered
    Mild to moderate disease: enthesitisMember has mild to moderate active psoriatic arthritis with enthesitis. Enthesitis is inflammation where tendons or ligaments attach to bone.Covered
    Severe diseaseMember has severe active psoriatic arthritis. The conventional synthetic DMARD pathway is not required when the member has severe disease.Covered
    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Tremfya
    Policy CodePolicy 2156-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the information required to initiate the Tremfya prior authorization review.
    SourceLink
    On This Page
    General Coverage RequirementsClinical Thresholds and EligibilityAuthorization, Documentation, and Denial RisksMedication and Policy ContextClinical DefinitionsInitial Therapy by IndicationContinuation Therapy by IndicationPrior Treatment Pathways
    Member has a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine, and acitretin.
    • Member has had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) administered at an adequate dose and duration.
    • Member has an intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine).
    • Member has enthesitis.
  1. Member has severe active psoriatic arthritis.
  2. Number of tender joints.
  3. Dactylitis.
  4. Enthesitis.
  5. Skin and/or nail involvement.
  6. Functional status.
  7. C-reactive protein (CRP).
  8. Minimum weightMembers must weigh at least 40 kg.
    Plaque psoriasisThe age and weight requirements apply to initial and continuation coverage for moderate to severe plaque psoriasis.
    Psoriatic arthritisThe age and weight requirements apply to initial coverage for active psoriatic arthritis.
  9. Ulcerative colitis or Crohn's disease: remission or low disease activity, or improvement in signs and symptoms from baseline.
  10. Prior Authorization

    Specialist Prescriber Requirement

    Tremfya must be prescribed by, or prescribed in consultation with, the required specialist for the treated indication.

    • Plaque psoriasis: dermatologist.
    • Psoriatic arthritis: rheumatologist or dermatologist.
    • Ulcerative colitis or Crohn's disease: gastroenterologist.

    Unsupported block type: prior_auth

    Documentation Required

    Universal Safety Requirements

    Before initiating applicable therapy, verify that the member has been evaluated for tuberculosis infection and that Tremfya will not be used with another biologic or targeted synthetic drug for the same indication.

    • TB evaluation is required before initiation of a biologic or targeted synthetic drug associated with increased TB risk.
    • Concomitant use with another biologic drug or targeted synthetic drug for the same indication is not permitted.
    Step Therapy

    Prior Biologic or Targeted Synthetic Therapy: Plaque Psoriasis

    For initial plaque psoriasis requests, document qualifying prior treatment with a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis.

    • Examples include Sotyktu and Otezla.
    • The member must be at least 6 years old and weigh at least 40 kg.
    Step Therapy

    Prior Biologic or Targeted Synthetic Therapy: Psoriatic Arthritis

    For initial psoriatic arthritis requests, document qualifying prior treatment with a biologic or targeted synthetic drug indicated for active psoriatic arthritis.

    • Examples include Rinvoq and Otezla.
    • The member must be at least 6 years old and weigh at least 40 kg.
    Step Therapy

    Plaque Psoriasis Conventional-Treatment Pathway

    For plaque psoriasis without qualifying prior biologic or targeted synthetic therapy, document that the member meets at least one disease-severity or treatment-history pathway.

    • Crucial body areas are affected, such as the hands, feet, face, neck, scalp, genitals or groin, or intertriginous areas.
    • At least 10% of body surface area is affected.
    • At least 3% of body surface area is affected and the member had an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin.
    • At least 3% of body surface area is affected and there is a clinical reason to avoid methotrexate, cyclosporine, and acitretin.
    Step Therapy

    Psoriatic Arthritis Conventional-Treatment Pathway

    For active psoriatic arthritis, document the applicable conventional-treatment or disease-severity pathway.

    • Mild to moderate disease with inadequate response to methotrexate, leflunomide, or another conventional synthetic DMARD at an adequate dose and duration.
    • Mild to moderate disease with intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic DMARD.
    • Mild to moderate disease with enthesitis.
    • Severe disease.

    Unsupported block type: prior_auth

    Documentation Required

    Plaque Psoriasis Initial Documentation

    For an initial plaque psoriasis request, submit documentation establishing the affected areas and extent of disease, along with prior-treatment information when applicable.

    • Chart notes or medical records documenting affected area(s) and body surface area affected, if applicable.
    • Chart notes, medical records, or claims history supporting medications previously tried and the response to therapy, if applicable.
    • If therapy is not advisable, document the clinical reason to avoid it.
    Documentation Required

    Plaque Psoriasis Continuation Documentation

    For plaque psoriasis continuation, document that the member is responding to Tremfya.

    • Chart notes or medical records showing decreased body surface area affected and/or improvement in signs and symptoms.
    Documentation Required

    Psoriatic Arthritis Initial Documentation

    For an initial psoriatic arthritis request, submit documentation of prior medications tried and the response or reason those therapies should be avoided.

    • Chart notes, medical records, or claims history supporting previous medications tried, if applicable, including response to therapy.
    • If therapy is not advisable, document the clinical reason to avoid it.
    Documentation Required

    Psoriatic Arthritis Continuation Documentation

    For psoriatic arthritis continuation, submit clinical documentation showing a positive response to Tremfya.

    • Document improvement from baseline in one or more relevant measures, such as swollen or tender joints, dactylitis, enthesitis, skin or nail involvement, functional status, or C-reactive protein.
    Documentation Required

    Inflammatory Bowel Disease Continuation Documentation

    For ulcerative colitis or Crohn's disease continuation, submit documentation showing remission or a positive clinical response to therapy.

    • Chart notes or medical records must support positive clinical response to therapy or remission.
    Documentation Required

    Crohn's Disease Response Documentation

    For Crohn's disease continuation, document remission or improvement from baseline consistent with low disease activity or a positive clinical response.

    • Relevant measures may include abdominal pain or tenderness, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance on endoscopy, CTE, MRE, or intestinal ultrasound, or improvement in a disease activity score such as CDAI.
    Documentation Required

    Safety and Concomitant-Therapy Documentation

    Document completion of the required TB evaluation and confirm that prohibited same-indication concomitant therapy is not being used.

    • Document TB evaluation before initiation of an applicable biologic or targeted synthetic drug.
    • Document that the member is not using another biologic drug or targeted synthetic drug for the same indication.
    Denial Risk

    Uncovered Indication

    Requests for indications other than moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis in adults, or moderately to severely active Crohn's disease in adults are considered experimental or investigational and not medically necessary.

    • Confirm that the requested use matches a listed covered indication before submitting the request.
    Denial Risk

    Prohibited Same-Indication Combination Therapy

    Do not use Tremfya concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • The restriction applies to all covered indications.
    Documentation Required

    Tuberculosis Evaluation Required

    Evaluate the member for tuberculosis infection before initiating a biologic or targeted synthetic drug associated with increased TB risk.

    • Retain documentation of the pre-treatment TB evaluation in the medical record.
    Denial Risk

    Insufficient Crohn's Disease Response

    Continuation authorization for Crohn's disease may be denied when the member has not achieved or maintained remission or a positive clinical response.

    • Insufficient response includes failure to demonstrate low disease activity or improvement in signs and symptoms from baseline.
    Denial Risk

    No Required TB Evaluation

    Authorization may be denied when the member has not received the required pre-treatment TB evaluation.

    • The evaluation must occur before initiation of the applicable biologic or targeted synthetic drug.
    Denial Risk

    Prohibited Concomitant Therapy

    Authorization may be denied when Tremfya is being used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Confirm that no prohibited same-indication combination therapy is being used.
    Disease context
    Enthesitis is considered alongside inadequate response, intolerance, or contraindication to conventional synthetic therapy.
    Positive clinical response
    DefinitionA positive clinical response is an objective or clinical reduction in disease activity.
    Clinical evidenceIt may be evidenced by low disease activity or improvement in signs and symptoms from baseline in at least one specified disease measure.
    RemissionFor ulcerative colitis or Crohn's disease, achieving or maintaining remission may also qualify for continuation authorization.
    Examples of measuresDisease measures include symptoms, laboratory results, body weight, mucosal appearance on endoscopy or imaging, and disease activity scores.

    Psoriatic Arthritis Continuation — 12-Month Authorization

    Authorization of 12 months may be granted, including for new members, when positive clinical response criteria are met.

    ALL of the following

    • Member is at least 6 years of age, weighs at least 40 kg, and is using the requested medication for psoriatic arthritis.Age >= 6 years; weight >= 40 kg
    • Member achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one of the following: swollen joints, tender joints, dactylitis, enthesitis, skin and/or nail involvement, functional status, or C-reactive protein.

    Ulcerative Colitis Continuation — 12-Month Authorization

    Authorization of 12 months may be granted, including for new members, when remission or positive clinical response criteria are met.

    ALL of the following

    • Member is using the requested medication for moderately to severely active ulcerative colitis.
    • Remission or positive clinical response

      • Member achieves or maintains remission.
      • Member achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one of the following: stool frequency, rectal bleeding, urgency of defecation, C-reactive protein, fecal calprotectin, mucosal appearance on endoscopy, CTE, MRE, or intestinal ultrasound, or a disease activity score such as UCEIS or Mayo score.

    Crohn's Disease Continuation — 12-Month Authorization

    Authorization of 12 months may be granted, including for new members, when remission or positive clinical response criteria are met.

    ALL of the following

    • Member is using the requested medication for moderately to severely active Crohn's disease.
    • Remission or positive clinical response

      • Member achieves or maintains remission.
      • Member achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one of the following: abdominal pain or tenderness, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance on endoscopy, CTE, MRE, or intestinal ultrasound, or a disease activity score such as CDAI.

    Crohn's Disease Continuation — 12-Month Authorization for All Members

    Continuation authorization may be granted for 12 months for all members, including new members, when the Crohn's disease response and all-indication safety requirements are met.

    ALL of the following

    • Requested medication is being used for moderately to severely active Crohn's disease.
    • Remission or positive clinical response

      • Member achieves or maintains remission.
      • Member achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one of the following: abdominal pain or tenderness, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance on endoscopy, CTE, MRE, or intestinal ultrasound, or a disease activity score such as CDAI.
    • Member has been evaluated for tuberculosis infection before initiation of a biologic or targeted synthetic drug associated with increased tuberculosis risk.
    • The requested medication is not used concomitantly with another biologic drug or targeted synthetic drug for the same indication.